Robert Califf

It looks like Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Eteplirsen may not be out of the woods just yet.  A letter from U.S. Food & Drug Administration Commissioner Robert Califf is calling for the drug's latest study to be retracted. The 13-page memo is dated Friday,...

Investors are often fickle figures on Twitter. It doesn't help if these people are invested in a volatile, erratic space such as biotech. Couple that with a niche drug, Daraprim, that treats a very serious disease in Toxoplasmosis (via AIDS) and you have your makings of a public groundswell. After...